NEWPORT's ISOPRINOSINE SECONF SET OF AIDS RELATED STUDIES

NEWPORT's ISOPRINOSINE SECONF SET OF AIDS RELATED STUDIES will be conducted under a compassionate IND. FDA announced in a May 10 "Talk Paper" that it recently "gave permission to Newport to initiate a compassionate-use protocol to give the drug to any physician for investigational use in patients with" Acquired Immune Deficiency Syndrome (AIDS). FDA said that in November it permitted initiation of an investigational protocol for Newport to test Isoprinosine (inosiplex) in a "limited number of patients with 'persistent generalized lymphadenopathy' and 'AIDS-related complex', syndromes which are believed to progress to AIDS in some cases." Newport said that while it did not have any data on the use of Isoprinosine for AIDS, FDA's approval of the firm's compassionate use protocol was based on the results of a preliminary lymphadenopathy trial at Mt. Sinai Hospital in New York. That trial found a statistically significant increase of immune system cells NK, T-11 and T-4 in Isoprinosine treated patients, the firm said. In announcing approval for compassionate use, FDA emphasized that it has never approved Isoprinosine for general public marketing for any medical purpose. The agency stated that Isoprinosine "is not a cure" for AIDS, but may be of value "as adjunctive therapy for some pre-AIDS or AIDS patients" because it stimulates the immune system. Isoprinosine is the only drug FDA has granted a compassionate IND for use in AIDS. FDA noted that "reports indicate some persons concerned about AIDS are going to Mexico to obtain the drug." The agency stated that "there is no need for anyone interested in obtaining Isoprinosine to leave the country. Any licensed physician who believes that the drug might be helpful for a patient may obtain it by contacting Newport. . .and enrolling their patient in one of Newport's protocols." Newport commented in a May 10 press release that "no final notification regarding the method and approval to initiate compassionate treatment with Isoprinosine for AIDS patients has been received." The firm stated that "discussions are underway with the FDA regarding a protocol to allow compassionate treatment of patients with fully developed AIDS to receive the drug." Newport's clinicals in pre-AIDS patients are currently underway. The firm said it is conducting double-blind placebo controlled studies in nine U.S. centers and one London center, and will possibly enlist patients for an additional two centers. FDA noted that Newport also has an active IND to test Isoprinosine in recurrent herpes virus infections, and has sought FDA's testing or marketing approval for use of the drug for learning and memory enhancement, multiple sclerosis, viral hepatitis, subacute sclerosing panencephalitis, infectious mononucleosis and influenza.

Welcome to Pink Sheet

Create an account to read this article

More from Archive

Ocaliva: Still No Clarity On Why EU Court Opposed Revocation Of Approval

 

Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By 

This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By 

We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.

Brazil Pilots Digital Drug Pack Inserts

 

A new pilot aims to take Brazil closer to ‘digital transformation.’

More from Pink Sheet

EMA Backs Gilead’s Yeytuo And 13 Other Drugs For EU Approval But Rejects Three

 

The European Medicines Agency’s human medicines committee, the CHMP, has recommended 14 new medicines for pan-EU approval this month, including five orphan medicines.

Lilly Wins EU Thumbs Up For Kisunla After EMA Reverses Rejection

 

The European Medicines Agency says that Eli Lilly's Alzheimer's disease drug should be approved for use in the EU, now that it has re-examined the negative opinion it previously adopted.

EMA Says ‘No’ To Roche/Sarepta’s Elevidys, US FDA Investigates Fourth Death

 

The European Medicines Agency recommended against pan-EU marketing authorization of Roche/Sarpeta’s gene therapy Elevidys for the treatment of Duchenne muscular dystrophy as the US reported another death in an Elevidys patient.